Jin Medical International Announces Share Combination Plan

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 23 hours ago

0mins

ZJYL-18.27%

Should l Buy ZJYL?

Source: PRnewswire

Share Combination Plan: Jin Medical International's Board of Directors has approved a 1-for-20 share combination aimed at enhancing the company's capital structure by reducing the number of outstanding shares, thereby improving compliance with Nasdaq listing requirements and market performance.
Authorized Capital Reclassification: Following the authorization from the extraordinary general meeting on January 30, 2026, the company will reclassify its authorized capital into Class A and Class B ordinary shares, totaling $50,000, reflecting strategic planning for future growth.
Shareholder Structure Change: Post-combination, the number of outstanding Class A ordinary shares will decrease from 136,547,100 to 6,827,355, while Class B ordinary shares will drop from 20,000,000 to 1,000,000, significantly increasing per-share value and boosting investor confidence.
New Trading Code Effective: The share combination will take effect on March 16, 2026, with Class A ordinary shares continuing to trade on Nasdaq under the existing symbol

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ZJYL?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ZJYL

About ZJYL

Jin Medical International Ltd is a holding company mainly engaged in the design and manufacturing of wheelchairs. The Company, through its wholly owned subsidiaries, is primarily engaged in the design, development, manufacturing and sales of wheelchair and other living aids products to be used by people with disabilities or impaired mobility. The Company's wheelchair product category includes mid, high and low-end wheelchairs. The wheelchair components include wheels and brakes, which are sold to customers for after-sales service. The living aids product category consists of oxygen concentrators, bath aids and rehabilitative devices. The Company mainly distributes its products in domestic and overseas markets.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Jin Medical International Approves Share Combination Plan

23 hours agoNewsfilter

Share Combination Plan: Jin Medical International's Board of Directors has approved a 1-for-20 share combination aimed at enhancing the company's capital structure by reducing the number of outstanding shares, thereby improving compliance with Nasdaq listing requirements and market performance.
Authorized Capital Reclassification: The reclassification divides the company's authorized capital into 45 million Class A ordinary shares and 5 million Class B ordinary shares, reflecting a strategic adjustment in capital structure that is expected to attract more investor interest.
Market Trading Arrangement: The stock combination will take effect on March 16, 2026, with Class A ordinary shares continuing to trade on Nasdaq under a consolidation-adjusted basis, and the new CUSIP number will be G5140V120, ensuring a smooth transition for investors.
Production Facility Expansion: Jin Medical's manufacturing facilities in Jiangsu and Anhui provinces will total 660,000 square feet, indicating the company's ongoing efforts to expand production capacity and market share to meet the growing demand from the disabled and elderly markets.

Jin Medical International Approves 1-for-20 Reverse Stock Split

9 hours agoNASDAQ.COM

Reverse Stock Split Plan: Jin Medical International Ltd. has approved a 1-for-20 reverse stock split, set to take effect on March 16, 2026, which will significantly reduce the number of outstanding shares as part of its effort to regain compliance with Nasdaq listing requirements.
Share Count Reduction: Following the split, the number of issued Class A shares will decrease from approximately 136.5 million to about 6.8 million, while Class B shares will shrink from 20 million to 1 million, thereby optimizing the company's capital structure.
Capital Structure Reclassification: The company has completed the reclassification of its authorized capital into dual-class shares and filed updated corporate documents with regulators in the Cayman Islands to reflect these changes, indicating a focus on strengthening its long-term capital framework.
Stock Price Fluctuation: ZJYL shares have traded between $0.11 and $1.02 over the past year, currently priced at $0.11, down 18.90%, reflecting market caution regarding the company's future prospects.

Jin Medical International Approves 1-for-20 Reverse Stock Split

10 hours agoseekingalpha

Reverse Stock Split Decision: Jin Medical International (ZJYL) has approved a 1-for-20 reverse stock split, set to take effect on March 16, 2026, which is expected to significantly reduce the total number of authorized and issued shares, potentially impacting shareholder structure profoundly.
Share Count Changes: Following the reverse split, Class A shares will decrease from 136.55 million to 6.83 million, while Class B shares will drop from 20 million to 1 million, a change that will notably increase the market value per share and may influence investor holding decisions.
Equity Structure Reclassification: The company has reclassified its share structure into dual classes, establishing 45 million Class A shares and 5 million Class B shares, aiming to enhance governance and operational flexibility, thereby increasing market appeal.
Market Reaction: Following the announcement of the reverse split, ZJYL's shares fell 16% in premarket trading, reflecting a cautious market sentiment regarding this decision, which could affect investor confidence and future financing capabilities.